These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32039671)

  • 1. Recent Advances in c-Jun N-Terminal Kinase (JNK) Inhibitors.
    Li G; Qi W; Li X; Zhao J; Luo M; Chen J
    Curr Med Chem; 2021; 28(3):607-627. PubMed ID: 32039671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
    Gehringer M; Muth F; Koch P; Laufer SA
    Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential.
    Bogoyevitch MA; Boehm I; Oakley A; Ketterman AJ; Barr RK
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):89-101. PubMed ID: 15023353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JNK signaling as a target for anticancer therapy.
    Abdelrahman KS; Hassan HA; Abdel-Aziz SA; Marzouk AA; Narumi A; Konno H; Abdel-Aziz M
    Pharmacol Rep; 2021 Apr; 73(2):405-434. PubMed ID: 33710509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling the Design and Discovery of c-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.
    Zhu Y; Shuai W; Zhao M; Pan X; Pei J; Wu Y; Bu F; Wang A; Ouyang L; Wang G
    J Med Chem; 2022 Mar; 65(5):3758-3775. PubMed ID: 35200035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galloyl benzamide-based compounds modulating tumour necrosis factor α-stimulated c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signalling pathways.
    Leo V; Stefanachi A; Nacci C; Leonetti F; de Candia M; Carotti A; Altomare CD; Montagnani M; Cellamare S
    J Pharm Pharmacol; 2015 Oct; 67(10):1380-92. PubMed ID: 26078032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors.
    Lombard CK; Davis AL; Inukai T; Maly DJ
    Biochemistry; 2018 Oct; 57(40):5897-5909. PubMed ID: 30211540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of c-Jun N-terminal kinases: an update.
    Koch P; Gehringer M; Laufer SA
    J Med Chem; 2015 Jan; 58(1):72-95. PubMed ID: 25415535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges.
    Bogoyevitch MA; Ngoei KR; Zhao TT; Yeap YY; Ng DC
    Biochim Biophys Acta; 2010 Mar; 1804(3):463-75. PubMed ID: 19900593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Jun N-terminal kinase activation in Xenopus laevis eggs and embryos. A possible non-genomic role for the JNK signaling pathway.
    Bagowski CP; Xiong W; Ferrell JE
    J Biol Chem; 2001 Jan; 276(2):1459-65. PubMed ID: 11029471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.
    Messoussi A; Feneyrolles C; Bros A; Deroide A; Daydé-Cazals B; Chevé G; Van Hijfte N; Fauvel B; Bougrin K; Yasri A
    Chem Biol; 2014 Nov; 21(11):1433-43. PubMed ID: 25442375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on JNK inhibitor patents: 2015 to present.
    Feng G; Yang X; Shuai W; Wang G; Ouyang L
    Expert Opin Ther Pat; 2024 Oct; 34(10):907-927. PubMed ID: 39223788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage.
    Waetzig V; Herdegen T
    Trends Pharmacol Sci; 2005 Sep; 26(9):455-61. PubMed ID: 16054242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JNK signalling: a possible target to prevent neurodegeneration.
    Borsello T; Forloni G
    Curr Pharm Des; 2007; 13(18):1875-86. PubMed ID: 17584114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor.
    Stebbins JL; De SK; Pavlickova P; Chen V; Machleidt T; Chen LH; Kuntzen C; Kitada S; Karin M; Pellecchia M
    J Med Chem; 2011 Sep; 54(18):6206-14. PubMed ID: 21815634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic promise of JNK ATP-noncompetitive inhibitors.
    Bogoyevitch MA
    Trends Mol Med; 2005 May; 11(5):232-9. PubMed ID: 15882611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships.
    Zeke A; Misheva M; Reményi A; Bogoyevitch MA
    Microbiol Mol Biol Rev; 2016 Sep; 80(3):793-835. PubMed ID: 27466283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
    Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arachidonic acid directly activates members of the mitogen-activated protein kinase superfamily in rabbit proximal tubule cells.
    Alexander LD; Cui XL; Falck JR; Douglas JG
    Kidney Int; 2001 Jun; 59(6):2039-53. PubMed ID: 11380805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities.
    Mehan S; Meena H; Sharma D; Sankhla R
    J Mol Neurosci; 2011 Mar; 43(3):376-90. PubMed ID: 20878262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.